Golvatinib

• Target:

  C-Met/HGFR|||VEGFR

• Related Pathways:

  Tyrosine Kinase/Adaptors|||Angiogenesis

• Purity:

  0.995

• Bioactivity:

  Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met/VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.

• Smiles:

  CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1

• Molecular Formula:

  C33H37F2N7O4

• Molecular Weight:

  633.69

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  928037-13-2